Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 70518-0224

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 70518-0224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Atorvastatin Calcium 10mg 70518 0224 00)

Label for Atorvastatin Calcium 10 mg oral film-coated tablets. The package contains 30 tablets and is labeled for prescription use only. Manufactured by Apotex Corp, repackaged by RemedyRepack Inc. in Indiana, PA. The label includes the NDC 70518-0224-00 and storage instructions between 20-25°C with permitted excursions.*

FDA Label Image

Mm2 (Atorvastatin Calcium 10mg 70518 0224 01)

Label for Atorvastatin Calcium 10 mg film-coated tablets, quantity 90, labeled by RemedyRepack Inc. The label includes NDC 70518-0224-01, manufacturer Apotex Corp., and storage instructions. It states refill Rx only and advises to see package insert for directions.*

FDA Label Image

Mm3 (Atorvastatin Calcium 10mg 70518 0224 02)

The packaging label for Atorvastatin Calcium 10 mg film-coated tablets, with a quantity of 28 tablets. The label shows the product is repackaged by RemedyRepack Inc. and includes manufacturer information for Apotex Corp. It also contains storage instructions and a QR code.*

FDA Label Image

Figure-01 (Figure 01)

A line graph depicting cumulative incidence (%) over time (years) comparing Atorvastatin (solid line) and Placebo (dashed line). The graph shows lower cumulative incidence for Atorvastatin, with a hazard ratio of 0.64 and a significance p-value of 0.0005.*

FDA Label Image

Figure-02 (Figure 02)

A Kaplan-Meier cumulative hazard plot comparing Atorvastatin and placebo groups over four years. The x-axis shows time to first primary endpoint in years, and the y-axis shows cumulative hazard percentage. The plot shows lower cumulative hazard for Atorvastatin vs. placebo, with a hazard ratio of 0.63 (95% CI 0.48-0.83) and p=0.001, indicating statistical significance.*

FDA Label Image

Figure-03 (Figure 03)

A line graph depicting the percentage of subjects experiencing an event over time (years) for atorvastatin 10 mg and 80 mg. The X-axis represents time to first major cardiovascular endpoint (0 to 5 years), and the Y-axis shows subjects experiencing the event (0 to 0.2%). The graph compares atorvastatin 10 mg (dashed line) and 80 mg (solid line) with a hazard ratio of 0.78 (0.69-0.89) and P=0.0002.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of atorvastatin calcium shown as a molecular diagram with labeled elements and bonds, including the calcium ion (Ca2+) and the atorvastatin molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.